Acute pancreatitis secondary prevention
|
Acute pancreatitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Acute pancreatitis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Acute pancreatitis secondary prevention |
|
Risk calculators and risk factors for Acute pancreatitis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monish Thuvooru Muthu Kalyanaraman, M.B.B.S[2]
Secondary Prevention
Overview
Recurrence prevention is the central goal of secondary prevention in acute pancreatitis (AP). Approximately 20–29% of patients experience recurrence after an index episode, and progression to chronic pancreatitis occurs in a substantial minority (higher after recurrent episodes), with risk greatest among smokers, alcohol users, and men.[1][2][3] The key modifiable interventions are cholecystectomy for biliary disease, alcohol and smoking cessation, triglyceride control, medication review, and systematic etiologic workup of idiopathic cases.[4][5]
Cholecystectomy for Biliary Pancreatitis
Same-admission cholecystectomy in mild gallstone pancreatitis reduces recurrent gallstone-related complications from 17% to 5% (PONCHO trial; RR 0.28).[4][1] Without cholecystectomy, 18% of patients are readmitted for biliary events, including 8% with recurrent pancreatitis.[4] The ACG 2024 guidelines recommend same-admission cholecystectomy as a key concept.[4] A 2026 Swedish nationwide study (n=9,593) confirmed same-admission cholecystectomy had the lowest recurrence (3.4%) compared with ERCP only (4.9%) or no intervention (17.5%).[6]
For moderately severe or severe biliary AP, cholecystectomy should be deferred until collections resolve or stabilize. A retrospective study of 248 such patients found recurrent biliary pancreatitis was reduced when cholecystectomy was performed before 8 weeks, and recurrent biliary events overall before 10 weeks.[1]
There is no conclusive evidence that biliary sphincterotomy alone reduces the rate of future biliary events overall, though it may lower short-term recurrent pancreatitis risk.[1][6] Cholecystectomy is recommended even after sphincterotomy; sphincterotomy alone is reserved for patients who are not surgical candidates.[4][1]
Cholecystectomy for Idiopathic Acute Pancreatitis
The ACG 2024 guidelines suggest cholecystectomy after a second episode of AP with no identifiable cause in patients fit for surgery (Key Concept #4).[4] A meta-analysis of 524 patients found recurrence was significantly lower after cholecystectomy than conservative management (11% vs 39%; RR 0.44; 95% CI 0.27–0.71), even after extensive workup including EUS and MRCP.[4][7] This implies current diagnostics are insufficient to exclude occult biliary disease, and cholecystectomy has a therapeutic role in idiopathic recurrent AP.[1]
Alcohol Cessation
Alcohol-related AP is an independent predictor of recurrence (HR 2.72; median 8.5 months to recurrence) and progression to chronic pancreatitis (HR 9.16).[8] The AGA strongly recommends brief alcohol intervention during the index admission. The supporting RCT used repeated counseling at 6-month intervals for 2 years, and this schedule is widely cited as the recommended approach.[9] An RCT demonstrated that repeated alcohol cessation counseling after discharge significantly reduced recurrence compared with a single discharge advisory.[10] A Japanese survey showed lower progression to chronic pancreatitis among those who completely abstained (13.6%) versus those who continued daily drinking at lower levels (23.3%) or maintained usual intake (40.9%).[10]
Smoking Cessation
Smoking is an independent risk factor for both recurrence (HR 4.09) and progression to chronic pancreatitis (HR 2.50).[11] Smoking and alcohol have synergistic effects on pancreatitis risk. Cessation counseling should be provided to all patients.[1][12]
Triglyceride Control
Hypertriglyceridemia (TG ≥1,000 mg/dL) accounts for 2–7% of AP and carries higher severity. The target for secondary prevention is TG <500 mg/dL to reduce recurrence risk.[13]
Guidelines recommend fibrates or prescription omega-3 fatty acids for severe hypertriglyceridemia (≥500 mg/dL) to reduce pancreatitis risk. Fenofibrate is preferred over gemfibrozil due to fewer drug interactions and lower myopathy risk when combined with statins. A very-low-fat diet is recommended for TG ≥1,000 mg/dL.[14][13]
The CORE-TIMI 72a/72b phase 3 trials (n=1,061 patients with severe HTG) demonstrated an 85% reduction in acute pancreatitis with olezarsen versus placebo (mean rate ratio 0.15; 95% CI 0.05–0.40; P<0.001), with NNT of 20 overall and 4 in the high-risk subgroup (TG ≥880 mg/dL with prior pancreatitis).[15]
Olezarsen (Tryngolza) is FDA-approved as an adjunct to diet for two indications: (1) to reduce TG in adults with FCS (80 mg subcutaneously monthly), and (2) to reduce TG and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (TG ≥500 mg/dL; 50 mg monthly, may increase to 80 mg). Notable safety signals include hypersensitivity reactions, dose-dependent liver enzyme elevations, thrombocytopenia (more common at 80 mg), and increases in HbA1c in patients with diabetes; monitoring of liver enzymes, platelet counts, and glycemic control is recommended.[16] Plozasiran (an siRNA targeting apoC-III) is also FDA-approved for FCS to reduce triglycerides, though its pancreatitis reduction has been less extensively characterized than olezarsen.[17]
Secondary causes of hypertriglyceridemia (uncontrolled diabetes, hypothyroidism, medications, alcohol) should be addressed concurrently.[14][13]
Medication Review
Drug-induced pancreatitis accounts for <5% of cases. Strongest evidence exists for didanosine, asparaginase, azathioprine, valproic acid, 6-mercaptopurine, and mesalamine. Misattribution is common — alternative causes should be excluded before attributing AP to a medication. If no alternative cause exists, withdrawal of the implicated drug is reasonable after discussion with the prescribing physician.[4][1][12]
Workup for Idiopathic and Recurrent AP
A systematic etiologic evaluation reduces the proportion of truly idiopathic cases:[4][5]
- Repeat transabdominal ultrasound after clinical recovery (gallstones and sludge may be missed on initial evaluation; sensitivity improves on repeat study)
- Repeat fasting triglycerides as an outpatient (initial hospital values may be falsely low due to NPO status)
- EUS — identifies etiology in most patients with recurrent IAP; assesses for microlithiasis, chronic pancreatitis, and neoplasms
- MRCP (including secretin-enhanced MRCP when available) — identifies anatomic anomalies, duct disruption, and pancreas divisum
- Genetic testing — may be useful when >1 family member has pancreatic disease or in young patients with recurrent AP; however, its role in routine management remains limited
- Routine ERCP should not be performed for diagnostic purposes due to the risk of precipitating pancreatitis
Patients with true recurrent idiopathic AP should be evaluated at centers of excellence with multidisciplinary expertise including advanced endoscopy and genetic testing.[4]
Progression to Chronic Pancreatitis
A systematic review found that 10% of patients with a first AP episode and 36% with recurrent AP develop chronic pancreatitis, with incidence rates of 1.4 per 100 person-years after first AP and 4.3 per 100 person-years after recurrent AP — a threefold increase.[1][2][3] Key risk factors for progression include alcohol use (HR 8.79), smoking (HR 2.50), age >60 (HR 5.29), and ≥3 recurrences in alcoholic RAP (HR 4.18).[11] There is also an increased lifetime risk of pancreatic cancer in patients with AP, likely driven by chronic inflammation.[1] For patients with refractory recurrent AP progressing to chronic pancreatitis and intractable pain, referral for consideration of total pancreatectomy with islet autotransplantation (TPIAT) may be appropriate at specialized centers.[4]
Clinically Actionable Recommendations
- Perform same-admission cholecystectomy for mild gallstone pancreatitis; defer in severe/necrotizing disease until collections resolve (ideally within 8–10 weeks).[4][1]
- After a second episode of idiopathic AP, consider cholecystectomy even if workup is negative — recurrence is reduced from ~39% to ~11%.[4][7]
- Provide brief alcohol intervention during the index admission; repeated counseling (e.g., at 6-month intervals for 2 years) further reduces recurrence.[9]
- Counsel on smoking cessation — smoking independently drives both recurrence and progression to chronic pancreatitis.[1][11]
- Target TG <500 mg/dL with fibrates (fenofibrate preferred), omega-3 fatty acids, and dietary modification; consider olezarsen for severe/refractory HTG or FCS, with monitoring for liver enzymes, platelet counts, and glycemic control.[14][15][16]
- Systematically evaluate idiopathic cases with repeat ultrasound, outpatient TG, EUS, and MRCP before labeling AP as truly idiopathic.[4][5]
- Refer patients with recurrent idiopathic AP to centers of excellence for advanced evaluation.[4]
- For refractory recurrent AP progressing to chronic pancreatitis with intractable pain, consider referral for TPIAT at specialized centers.[4]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 Trikudanathan G, Yazici C, Evans Phillips A, Forsmark CE (2024). "Diagnosis and Management of Acute Pancreatitis". Gastroenterology. 167 (4): 673–688. doi:10.1053/j.gastro.2024.02.052. PMID 38734348 Check
|pmid=value (help). - ↑ 2.0 2.1 Sankaran SJ, Xiao AY, Wu LM; et al. (2015). "Frequency of Progression From Acute to Chronic Pancreatitis and Risk Factors: A Meta-Analysis". Gastroenterology. 149 (6): 1490–1500.e1. doi:10.1053/j.gastro.2015.07.066. PMID 26248030.
- ↑ 3.0 3.1 Gagyi EB, Teutsch B, Veres DS; et al. (2024). "Incidence of Recurrent and Chronic Pancreatitis After Acute Pancreatitis: A Systematic Review and Meta-Analysis". Therap Adv Gastroenterol. 17: 17562848241255303. doi:10.1177/17562848241255303.
- ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 4.15 Tenner S, Vege SS, Sheth SG; et al. (2024). "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis". Am J Gastroenterol. 119 (3): 419–437. doi:10.14309/ajg.0000000000002645. PMID 38301252 Check
|pmid=value (help). - ↑ 5.0 5.1 5.2 Boxhoorn L, Voermans RP, Bouwense SA; et al. (2020). "Acute Pancreatitis". Lancet. 396 (10252): 726–734. doi:10.1016/S0140-6736(20)31310-6. PMID 32682482 Check
|pmid=value (help). - ↑ 6.0 6.1 Selin D, Oskarsson V, Maret-Ouda J; et al. (2026). "Cholecystectomy vs Endoscopic Retrograde Cholangiopancreatography or No Intervention After Gallstone-Related Acute Pancreatitis". JAMA Surg. doi:10.1001/jamasurg.2026.2168.
- ↑ 7.0 7.1 Umans DS, Hallensleben ND, Verdonk RC; et al. (2020). "Recurrence of Idiopathic Acute Pancreatitis After Cholecystectomy: Systematic Review and Meta-Analysis". Br J Surg. 107 (3): 191–199. doi:10.1002/bjs.11429. PMID 31912875.
- ↑ Mederos MA, Reber HA, Girgis MD (2021). "Acute Pancreatitis: A Review". JAMA. 325 (4): 382–390. doi:10.1001/jama.2020.20317. PMID 33464334 Check
|pmid=value (help). - ↑ 9.0 9.1 Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN (2018). "American Gastroenterological Association Institute Guideline On Initial Management of Acute Pancreatitis". Gastroenterology. 154 (4): 1096–1101. doi:10.1053/j.gastro.2018.01.032.
- ↑ 10.0 10.1 Wang F, Görgülü K, Algül H, Hu LH (2026). "The Role of Alcohol in Pancreatic Diseases: A Comprehensive Perspective". Gastroenterology. 170 (2): 268–286. doi:10.1053/j.gastro.2025.08.025.
- ↑ 11.0 11.1 11.2 Park JY, Bang S, Jeon TJ, Cho JH, Lee KJ (2025). "Risk of and Factors Influencing the Progression From Acute to Recurrent Acute to Chronic Pancreatitis". Pancreatology. doi:10.1016/j.pan.2025.04.004.
- ↑ 12.0 12.1 Forsmark CE, Vege SS, Wilcox CM (2016). "Acute Pancreatitis". N Engl J Med. 375 (20): 1972–1981. doi:10.1056/NEJMra1505202. PMID 27959604.
- ↑ 13.0 13.1 13.2 Gligorijevic N, Stefanovic-Racic M, Kershaw EE (2023). "Medical Management of Hypertriglyceridemia in Pancreatitis". Curr Opin Gastroenterol. 39 (5): 421–427. doi:10.1097/MOG.0000000000000956.
- ↑ 14.0 14.1 14.2 Berglund L, Brunzell JD, Goldberg AC; et al. (2012). "Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 97 (9): 2969–2989. doi:10.1210/jc.2011-3213.
- ↑ 15.0 15.1 Marston NA, Bergmark BA, Alexander VJ; et al. (2025). "Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk". N Engl J Med. doi:10.1056/NEJMoa2512761.
- ↑ 16.0 16.1 "TRYNGOLZA (olezarsen) prescribing information". U.S. Food and Drug Administration. 2025. Missing or empty
|url=(help) - ↑ Tsimikas S (2025). "Anti-apoC-Iii Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease". Curr Atheroscler Rep. 27 (1): 103. doi:10.1007/s11883-025-01345-4.